Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and future concepts in hepatitis C therapy.

Jean-Michel Pawlotsky1

  • 1Department of Virology, INSERM U635, Hôpital Henri Mondor, Université Paris XII, 51 avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France. jean-michel.pawlotsky@hmn.aphp.fr

Seminars in Liver Disease
|February 26, 2005
PubMed
Summary

Achieving permanent hepatitis C virus (HCV) eradication requires new therapies beyond current interferon and ribavirin treatments. Future HCV treatments will focus on tailored drug combinations for improved viral clearance and patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dried Blood Spot: A Tool to Ensure Broad Access to Hepatitis D Screening, Diagnosis, and Treatment Monitoring.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France.

The Lancet. Microbe·2026
Same author

Prospective multicentre study of upper respiratory mucosal transcriptomics reveals two major endotypes of critically ill COVID-19 patients.

Communications medicine·2026
Same author

Indeterminate Phase/Grey Zone of Chronic Hepatitis B: Clinical Features, Outcomes and Molecular Insights.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Hepatitis C virus elimination: So close, so far?

Antiviral research·2026
Same author

Hepatitis D Virus Seroconversion Rate Among People With Chronic Hepatitis B Virus Infection in France and The Gambia (Inci-D).

Open forum infectious diseases·2026

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) therapy aims for permanent viral eradication using multi-action drug combinations.
  • Current treatments like pegylated interferon-alpha and ribavirin, while combining multiple mechanisms, do not achieve sustained viral clearance in many patients.
  • Novel therapeutic strategies are essential for improving HCV treatment efficacy.

Purpose of the Study:

  • To review the limitations of current HCV therapies.
  • To outline the next generation of anti-HCV therapeutic agents.
  • To emphasize the need for personalized treatment approaches.

Main Methods:

  • Review of existing and emerging HCV therapeutic strategies.
  • Analysis of drug mechanisms of action (antiviral, anti-infection, cell clearance).

Related Experiment Videos

  • Discussion of future treatment categories including new interferons, ribavirin alternatives, direct HCV inhibitors, and immune therapies.

    • Main Results:

    • Current combination therapies are insufficient for complete HCV eradication in a significant patient subset.
    • Next-generation HCV treatments will likely include novel interferons, ribavirin alternatives, direct-acting antivirals, and immunotherapies.
    • Personalized treatment regimens, considering patient parameters and viral kinetics, are predicted for future HCV management.

    Conclusions:

    • Complete eradication of hepatitis C virus remains the primary goal of therapy.
    • Next-generation therapies will offer diverse mechanisms of action and improved tolerability.
    • Tailored drug combinations based on individual patient data will enhance sustained virologic response rates.